{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:04:08Z","timestamp":1790676248208,"version":"4.1.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Despite similar histologic appearance among high-grade serous ovarian cancers (HGSOCs), clinical observations suggest vast differences in gross appearance. There is currently no systematic framework by which to classify HGSOCs according to their gross morphologic characteristics.<\/jats:p><\/jats:sec>Objective<\/jats:title>To develop and characterize a gross morphologic classification system for HGSOC.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study included patients with suspected advanced-stage ovarian cancer who presented between April 1, 2013, and August 5, 2016, to the University of Texas MD Anderson Cancer Center, a large referral center. Patients underwent laparoscopic assessment of disease burden before treatment and received a histopathologic diagnosis of HGSOC. Researchers assigning morphologic subtype and performing molecular analyses were blinded to clinical outcomes. Data analysis was performed between April 2020 and November 2021.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Gross tumor morphologic characteristics.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Clinical outcomes and multiomic profiles of representative tumor samples of type I or type II morphologic subtypes were compared.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 112 women (mean [SD] age 62.7 [9.7] years) included in the study, most patients (84% [94]) exhibited a predominant morphologic subtype and many (63% [71]) had a uniform morphologic subtype at all involved sites. Compared with those with uniform type I morphologic subtype, patients with uniform type II morphologic subtype were more likely to have a favorable Fagotti score (83% [19 of 23] vs 46% [22 of 48]; P<\/jats:italic>\u2009=\u2009.004) and thus to be triaged to primary tumor reductive surgery. Similarly, patients with uniform type II morphologic subtype also had significantly higher mean (SD) estimated blood loss (639 [559; 95% CI, 391-887] mL vs 415 [527; 95% CI, 253-577] mL; P<\/jats:italic>\u2009=\u2009.006) and longer mean (SD) operative time (408 [130; 95% CI, 350-466] minutes vs 333 [113; 95% CI, 298-367] minutes; P<\/jats:italic>\u2009=\u2009.03) during tumor reductive surgery. Type I tumors had enrichment of epithelial-mesenchymal transition (false discovery rate [FDR] q-value, 3.10\u2009\u00d7\u200910\u221224<\/jats:sup>), hypoxia (FDR q-value, 1.52\u2009\u00d7\u200910\u22125<\/jats:sup>), and angiogenesis pathways (FDR q-value, 2.11\u2009\u00d7\u200910\u22122<\/jats:sup>), whereas type II tumors had enrichment of pathways related to MYC signaling (FDR q-value, 2.04\u2009\u00d7\u200910\u22129<\/jats:sup>) and cell cycle progression (FDR q-value, 1.10\u2009\u00d7\u200910\u22125<\/jats:sup>) by integrated proteomic and transcriptomic analysis. Abundances of metabolites and lipids also differed between the 2 morphologic subtypes.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study identified 2 novel, gross morphologic subtypes of HGSOC, each with unique clinical features and molecular signatures. The findings may have implications for triaging patients to surgery or chemotherapy, identifying outcomes, and developing tailored therapeutic strategies.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.36626","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T15:34:20Z","timestamp":1665761660000},"page":"e2236626","source":"Crossref","is-referenced-by-count":24,"title":["Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics"],"prefix":"10.1001","volume":"5","author":[{"given":"Katelyn F.","family":"Handley","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa"},{"name":"Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis T.","family":"Sims","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.","family":"Bateman","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, Virginia"},{"name":"Gynecologic Cancer Center of Excellence, Henry M. Jackson Foundation, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Glassman","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine I.","family":"Foster","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"Fellman","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Conrads","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, Virginia"},{"name":"Gynecologic Cancer Center of Excellence, Henry M. Jackson Foundation, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Hood","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, Virginia"},{"name":"Gynecologic Cancer Center of Excellence, Henry M. Jackson Foundation, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Barakat","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, Virginia"},{"name":"Gynecologic Cancer Center of Excellence, Henry M. Jackson Foundation, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Celestino","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Rangel","sequence":"additional","affiliation":[{"name":"Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Badal","sequence":"additional","affiliation":[{"name":"Department of Chemistry, The University of Texas at Austin, Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Chemistry, The University of Texas at Austin, Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prahlad T.","family":"Ram","sequence":"additional","affiliation":[{"name":"Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, Virginia"},{"name":"Gynecologic Cancer Center of Excellence, Henry M. Jackson Foundation, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia S.","family":"Eberlin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Andrew","family":"Futreal","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert C.","family":"Bast","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole D.","family":"Fleming","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Conrads","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, Virginia"},{"name":"Gynecologic Cancer Center of Excellence, Henry M. Jackson Foundation, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"8","key":"zoi221039r1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi221039r2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/AOG.0000000000002796","article-title":"Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer.","volume":"132","author":"Fleming","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"8","key":"zoi221039r3","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"zoi221039r4","doi-asserted-by":"publisher","first-page":"642.e1","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"zoi221039r5","doi-asserted-by":"publisher","first-page":"462.e1","DOI":"10.1016\/j.ajog.2013.07.016","article-title":"A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer.","volume":"209","author":"Fagotti","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"zoi221039r6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.","volume":"4","author":"Huang","year":"2009","journal-title":"Nat Protoc"},{"issue":"1","key":"zoi221039r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.","volume":"37","author":"Huang","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"zoi221039r8","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies.","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"zoi221039r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.066","article-title":"Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer.","volume":"31","author":"Lee","year":"2020","journal-title":"Cell Rep"},{"issue":"5","key":"zoi221039r10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s13361-013-0607-z","article-title":"MSiReader: an open-source interface to view and analyze high resolving power MS imaging files on Matlab platform.","volume":"24","author":"Robichaud","year":"2013","journal-title":"J Am Soc Mass Spectrom"},{"issue":"16","key":"zoi221039r11","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","article-title":"Statistical significance for genomewide studies.","volume":"100","author":"Storey","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"zoi221039r12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data.","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"24","key":"zoi221039r13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249492","article-title":"Hypoxia-mediated decrease of ovarian cancer cells reaction to treatment: significance for chemo- and immunotherapies.","volume":"21","author":"Klemba","year":"2020","journal-title":"Int J Mol Sci"},{"key":"zoi221039r14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.thromres.2016.12.002","article-title":"Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression.","volume":"150","author":"Swier","year":"2017","journal-title":"Thromb Res"},{"issue":"2","key":"zoi221039r15","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e32","article-title":"Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.","volume":"29","author":"Li","year":"2018","journal-title":"J Gynecol Oncol"},{"issue":"14","key":"zoi221039r16","first-page":"3847","article-title":"The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models.","volume":"63","author":"Gatenby","year":"2003","journal-title":"Cancer Res"},{"key":"zoi221039r17","doi-asserted-by":"publisher","first-page":"24S","DOI":"10.2967\/jnumed.107.047258","article-title":"Causes and consequences of increased glucose metabolism of cancers.","volume":"49","author":"Gillies","year":"2008","journal-title":"J Nucl Med"},{"issue":"29","key":"zoi221039r18","doi-asserted-by":"publisher","first-page":"27613","DOI":"10.18632\/oncotarget.v6i29","article-title":"Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.","volume":"6","author":"Barger","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"zoi221039r19","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1097\/IGC.0000000000001063","article-title":"Targeting FOXM1 improves cytotoxicity of paclitaxel and cisplatinum in platinum-resistant ovarian cancer.","volume":"27","author":"Westhoff","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"zoi221039r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096989","article-title":"FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer.","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"zoi221039r21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0093-7754(02)70065-1","article-title":"Role of angiogenesis in tumor growth and metastasis.","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"issue":"4","key":"zoi221039r22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/PPO.0000000000000138","article-title":"The contribution of angiogenesis to the process of metastasis.","volume":"21","author":"Bielenberg","year":"2015","journal-title":"Cancer J"},{"issue":"4","key":"zoi221039r23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.7150\/jca.26478","article-title":"Aberrant activation of hedgehog signalling promotes cell migration and invasion via matrix metalloproteinase-7 in ovarian cancer cells.","volume":"10","author":"Zhang","year":"2019","journal-title":"J Cancer"},{"issue":"5-6","key":"zoi221039r24","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1002\/jcb.v121.5-6","article-title":"Interference with SMO increases chemotherapy drug sensitivity of A2780\/DDP cells by inhibiting the Hh\/Gli signaling pathway.","volume":"121","author":"Ma","year":"2020","journal-title":"J Cell Biochem"},{"issue":"1","key":"zoi221039r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/MCB.19.1.1","article-title":"c-Myc target genes involved in cell growth, apoptosis, and metabolism.","volume":"19","author":"Dang","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"7239","key":"zoi221039r26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism.","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"issue":"10","key":"zoi221039r27","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/gb-2003-4-10-r69","article-title":"An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.","volume":"4","author":"Zeller","year":"2003","journal-title":"Genome Biol"},{"issue":"2","key":"zoi221039r28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"zoi221039r29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance mechanisms to anti-angiogenic therapies in cancer.","volume":"10","author":"Haibe","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"zoi221039r30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-020-00932-z","article-title":"Beyond thrombosis: the impact of tissue factor signaling in cancer.","volume":"13","author":"Unruh","year":"2020","journal-title":"J Hematol Oncol"},{"key":"zoi221039r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the Warburg effect supports aggressiveness and drug resistance of cancer cells?","volume":"38","author":"Icard","year":"2018","journal-title":"Drug Resist Updat"},{"key":"zoi221039r32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canep.2015.11.014","article-title":"Hedgehog signaling pathway as a therapeutic target for ovarian cancer.","volume":"40","author":"Li","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"zoi221039r33","doi-asserted-by":"publisher","first-page":"549412","DOI":"10.1155\/2015\/549412","article-title":"Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies.","volume":"2015","author":"Zimna","year":"2015","journal-title":"Biomed Res Int"},{"issue":"1","key":"zoi221039r34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/pathmechdis.2018.13.issue-1","article-title":"Epithelial mesenchymal transition in tumor metastasis.","volume":"13","author":"Mittal","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"zoi221039r35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside.","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"zoi221039r36","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/cmdc.v5:4","article-title":"Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics.","volume":"5","author":"Peukert","year":"2010","journal-title":"ChemMedChem"},{"issue":"6","key":"zoi221039r37","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1177\/1078155220951845","article-title":"Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer.","volume":"27","author":"Guenter","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"zoi221039r38","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.49","article-title":"Lipid metabolic reprogramming in cancer cells.","volume":"5","author":"Beloribi-Djefaflia","year":"2016","journal-title":"Oncogenesis"},{"issue":"21","key":"zoi221039r39","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1073\/pnas.1507228112","article-title":"MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.","volume":"112","author":"Shroff","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"zoi221039r40","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1021\/ac400479j","article-title":"Characterization of MYC-induced tumorigenesis by in situ lipid profiling.","volume":"85","author":"Perry","year":"2013","journal-title":"Anal Chem"},{"issue":"29","key":"zoi221039r41","doi-asserted-by":"publisher","first-page":"10450","DOI":"10.1073\/pnas.1409778111","article-title":"Alteration of the lipid profile in lymphomas induced by MYC overexpression.","volume":"111","author":"Eberlin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"zoi221039r42","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1158\/1535-7163.MCT-14-0801","article-title":"Targeting c-MYC in platinum-resistant ovarian cancer.","volume":"14","author":"Reyes-Gonz\u00e1lez","year":"2015","journal-title":"Mol Cancer Ther"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797315\/handley_2022_oi_221039_1664988089.59724.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T15:34:25Z","timestamp":1665761665000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36626","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}